Key TAVR Highlights at ACC.25
Key TAVR Highlights at ACC.25
Highlighted by AHA.
1. Major TAVR Companies Presenting New Data
• Medtronic and Edwards Lifesciences, the two leading TAVR companies, will showcase their latest research and innovations at ACC.25 (March 29–31, Chicago).
• Medtronic’s Evolut valves and Edwards’ Sapien 3 valves remain the dominant TAVR platforms in the U.S.
• New clinical data will be presented, focusing on long-term TAVR outcomes, early treatment for AS, and technological advancements.
2. Medtronic’s Key Presentations
• Evolut Low Risk Trial (Five-Year Data) – March 30, 10:30 a.m.
• Long-term outcomes comparing TAVR (Evolut) to surgical aortic valve replacement (SAVR) in low-risk patients.
• Previously, four-year results confirmed TAVR’s safety, effectiveness, and cost efficiency.
• The five-year results will be a major highlight, providing further evidence on TAVR’s durability.
• Medtronic emphasizes superior valve performance, better patient outcomes, and robust clinical evidence supporting its TAVR technology.
3. Edwards Lifesciences’ Key Presentations
• EARLY TAVR Study (March 31, 11:00 a.m. & 1:48 p.m.)
• Investigates the benefits of performing TAVR in asymptomatic severe AS patients instead of waiting for symptoms to appear.
• Two presentations will explore:
1. Early conversions to TAVR – Why some patients in the study had to undergo TAVR sooner than expected.
2. Biomarker-based risk assessment – How biomarkers (e.g., BNP, troponin) predict AS progression and help identify high-risk patients.
• Electronic Provider Notifications for AS Detection (March 30, 2:15 p.m.)
• Evaluates automated alerts in electronic medical records to detect severe AS earlier.
• Could improve early diagnosis, faster referrals, and better patient outcomes.
4. ‘The Future of TAVR’ Session – March 30, 3:30 p.m.
• A dedicated session discussing emerging trends in TAVR, including:
• Expanding TAVR to moderate AS patients (PROGRESS & EXPAND TAVR II trials).
• Potential to prevent cardiac fibrosis and heart failure in earlier-stage AS.
• Long-term evolution of TAVR vs. SAVR in treatment strategies.
• Experts will provide insights into how TAVR is reshaping valvular heart disease management.
Conclusion
ACC.25 will showcase critical TAVR advancements, particularly regarding early intervention, long-term durability, and AI-driven detection. Medtronic and Edwards Lifesciences continue to push innovation in valve performance, patient selection, and clinical outcomes, setting the stage for TAVR’s expanding role in cardiology.
For more information about ACC.25, including registration details and a full schedule. https://accscientificsession.acc.org/
